The board of directors of Mabpharm Limited announced board changes. With effect from July 10, 2024, Mr. Cen Jialin (?Mr. Cen?) and Dr. Tao Qian (?Dr. Tao?) will be appointed as a non-executive Director and an independent non-executive Director respectively. Mr. Cen Jialin, aged 49, currently serves as an executive director of CDH Investments.

From August 2002 to September 2004, Mr. Cen served as the manager of the operation and procurement department in Shenzhen branch of AEON (China) Co. Ltd. From January 2006 to April 2007, Mr. Cen served as the general manager in charge of the retail division in Chongqing branch and Maoming branch of CapitaLand China. From March 2007 to March 2018, Mr. Cen served as the general manager of Skycity Group.

Mr. Cen has been an executive director of CDH Investments since April 2018. Mr. Cen obtained a bachelor's degree in finance and securities from Shenzhen University in July 1999 and obtained a master's degree in business administration from Washington University in St. Louis in December 2012.

Dr. Tao Qian, aged 58, currently serves as a professor of department of clinical oncology at The Chinese University of Hong Kong. Dr. Tao is a leader in cancer epigenetics and tumor suppressor genes study in Asia and has published 189 journal articles and 5 book chapters with over 14,000 citations. Dr. Tao served as a research associate at Shantou University Medical College from 1988 to 1990 and a lecturer from 1990 to 1991 at the aforementioned university.

Dr. Tao served as an assistant professor of department of oncology at Johns Hopkins School of Medicine from February 1999 to August 2004 and a consultant from August 2004 to November 2006 at the aforementioned university. Dr. Tao served as an adjunct associate professor of department of microbiology at the National University of Singapore from 2001 to 2004. Dr. Tao also served as an associate professor of department of clinical oncology at The Chinese University of Hong Kong from August 2004 to August 2008.

Dr. Tao obtained a bachelor's degree in biology from Hunan Normal University in July 1985 and obtained a master degree in genetics from Xiamen University in August 1988. Dr. Tao was awarded a doctor of philosophy in molecular pathology and virology from The University of Hong Kong in November 1996 and has been a postdoctoral fellow at Sidney Kimmel Comprehensive Cancer Center from September 1995 to February 1999. The board announced that Dr. Qian Weizhu (?Dr. Qian?), currently a non-executive Director of the Company, will be re-designated as an executive Director.

Dr. Qian Weizhu, aged 48, was appointed as a non-executive director of the Company and a director of Taizhou Mabtech Pharmaceutical Limited and Shanghai Shengheng Biotechnology Limited in November 2023 and is responsible for participating in the formulation of the Group's business and corporate strategies. Dr. Qian has more than 25 years of experience in oncology and biology fields. Dr. Qian was employed at the Cancer Institute of Second Military Medical University from 1994 to 2013, primarily responsible for biotechnology research and development.

Dr. Qian consecutively served as deputy general manager and general manager of Shanghai Zhangjiang Biotechnology Co. Ltd. from January 2014 to July 2017. Dr. Qian worked as a director and general manager in Shanghai Biomabs Pharmaceuticals Co.

Ltd. (?Biomabs?) from October 2015 to August 2018 and from December 2020 to October 2023, and as the vice president of Shanghai Mabstar Biotechnology Co. Ltd. from November 2023 to July 2024. Dr. Qian also served as general manager in Shanghai Sinomab Biotechnology Co.

Ltd. (?MTJA?) from February 2016 to August 2018. Dr. Qian was a legal representative of Shanghai Guojian Biotechnology Research Institute from February 2015 to September 2018. Dr. Qian joined Group in February 2015, and served consecutively as a director and chairman of the board of directors in Taizhou Pharmaceutical from February 2015 to October 2020, during which she had been deputy general manager and general manager of Taizhou Pharmaceutical consecutively from February 2015 to August 2018.

Dr. Qian served as a director and general manager of Shengheng Biotech from August 2018 to October 2020. Dr. Qian served as the executive director and chief executive officer of the Company from July 2018 to October 2020 and served as a member of the nomination committee of the Company from the listing date of the Company (being May 31, 2019) to October 2020. Dr. Qian obtained a master's degree in biochemistry and molecular biology in June 2003 from Second Military Medical University and was awarded a doctorate degree in oncology in June 2011 from the aforementioned university.